Key Highlights
- Elevance Health (NYSE:ELV) fell 7.63% on November 18, while Centene dropped 7.03% and CVS Health 5.20%.
- Molina Healthcare was down about 4.97% in the afternoon as selling spread across managed care.
- The CMS proposal, known as the CRUSH rule, would extrapolate Medicare Advantage audit errors to whole contracts back to 2018.
- CMS estimates recoveries of about USD 90.2 billion from 2027 through 2036, and comments close on January 19, 2027.
The Selling Spreads Beyond the Leaders
The largest declines on Wednesday were in Humana and UnitedHealth, but the CMS proposal also weighed heavily on the rest of the managed care group. Elevance Health fell 7.63%, Centene 7.03% and CVS Health, which owns Aetna, 5.20%. Molina Healthcare was down 4.97% early in the afternoon. The health care sector lost 2.20%, making it the second worst performer in the S&P 500 after energy. The size of each decline broadly tracked how much each company relies on Medicare Advantage relative to its other businesses. Elevance has a large commercial and Medicaid business, which gives it some balance, but it has also been growing its Medicare Advantage membership in recent years. Centene's exposure comes through its Medicare plans, which are smaller than its Medicaid and marketplace operations. CVS Health's decline was cushioned by its pharmacy and benefits management businesses. The breadth of the move showed that investors see the proposal as an industry issue rather than a problem for one or two companies. Investors appear to be treating the whole group as exposed until each company explains its own position.
What the CRUSH Rule Would Do
The Centers for Medicare and Medicaid Services announced the proposal on November 16. It targets improper payments in Medicare Advantage, where plans receive higher payments for members with more documented health conditions. Audits check whether those conditions are supported by medical records. Under the proposal, the error rate found in a sample would be extrapolated across the whole contract, which can turn a small sample finding into a large repayment. The approach would apply to payments starting in 2018. CMS said a federal court in Texas set aside similar provisions of a 2023 rule on procedural grounds and that it is reissuing them. The agency estimates the rule would recover about USD 90.2 billion from 2027 through 2036. The proposal is scheduled for publication in the Federal Register on November 19, and public comments are due by January 19, 2027. That timeline means the final rule, and any change to it, is unlikely before early next year at the earliest.
How Investors May Respond
In the near term, the shares are likely to trade on estimates of each company's exposure. Insurers have not yet set out how much of the USD 90.2 billion they might owe, and those figures will matter for valuations. Many investors had already reduced holdings in managed care this year because of rising medical costs, so some of the risk may have been priced in before this week. Still, the size of the moves suggests that a two-day drop of this scale was not fully expected. Another Factor is interest rates. With the 10-year Treasury Yield near 5.07% and the Fed minutes signalling more hikes, defensive sectors such as health care are competing with higher bond yields for income investors. Legal action is also possible, given the court ruling against the earlier rule. Over the coming weeks, investors will look for company statements, industry comments and any signs from Washington that the proposal could be narrowed before it is finalised. Until then, the group is likely to remain one of the most volatile parts of the health care sector.
Where Things Stand
Elevance, Centene, CVS Health and Molina fell as the CRUSH rule threatened large Medicare Advantage repayments. Exposure estimates and the January 19, 2027 comment deadline are the next markers.






Please wait processing your request...